Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 jun 2015 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients
Bericht
Mechelen, Belgium; 18 June 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced today it has completed recruitment for the Phase 2 Proof-of-Concept study in ulcerative colitis with GPR84 inhibitor GLPG1205, a potential novel treatment for inflammatory bowel diseases. Topline results from this study are now expected in Q1 2016. GPR84 was identified as a target for these diseases through Galapagos' target discovery platform and GLPG1205 is fully proprietary to Galapagos.
GLPG1205 ('1205) inhibits GPR84, a novel mechanism of action for the treatment of inflammatory bowel diseases (IBD). GPR84 is upregulated in IBD patients. Galapagos has shown that '1205, a selective inhibitor of GPR84, is very effective in pre-clinical models for IBD. In Phase 1 studies, once-daily oral '1205 showed good safety, full blockage of GPR84, and favorable drug-like properties.
Datum laatste update: 02 september 2024